Increased prevalence of celiac disease and its clinical picture among patients with diabetes mellitus type 1 - observations from a single pediatric center in Central Europe by Wędrychowicz, Anna et al.
1






Conflict of interests: none declared.
Original paper | Praca oryginalna
Pediatr Endocrinol Diabetes Metab 2021; 27 (1): 1–6 
DOI: https://doi.org/10.5114/pedm.2020.103113
Anna Wędrychowicz, Joanna Nazim 
Institute of Pediatrics 
Department of Endocrinology of Children and Adolescents




Increased prevalence of celiac disease and its clinical picture among patients 
with diabetes mellitus type 1 – observations from a single pediatric center  
in Central Europe 
Zwiększona częstość występowania celiakii i jej obraz kliniczny u pacjentów z cukrzycą typu 1 – 
obserwacje z pojedynczego ośrodka pediatrycznego w Europie Centralnej
1,2Anna Wędrychowicz, 3Mari Minasyan, 3Alicja Pietraszek, 3Janusz Centkowski, 3Maria Stręk, 
3Joanna Różańska, 3Kamila Chełmecka, 3Barbara Zdzierak, 3Marcelina Wilk, 3Patrycja Czekańska, 
3Peter Pacut, 4Zofia Grzenda-Adamek, 2Jadwiga Małek, 2Marta Ciechanowska, 2Małgorzata Stelmach, 
1,2Joanna Nazim, 3Jerzy B. Starzyk
1Department of Endocrinology of Children and Adolescents, Jagiellonian University Collegium Medicum, 
Institute of Pediatrics, Krakow, Poland
2Department of Endocrinology of Children and Adolescents, University Children’s Hospital in Krakow, Poland
3Student Science Circle, Department of Endocrinology of Children and Adolescents, Jagiellonian University 
Collegium Medicum, Institute of Pediatrics, Krakow, Poland
4Department of Pediatrics, Gastroenterology and Nutrition, University Children’s Hospital in Krakow, Poland
Abstract
The aim of our study was to analyze the incidence and the clinical characteristic of celiac disease (CD) in pediatric population with 
type 1 diabetes mellitus (T1DM). 
Materials and methods: The data of 880 patients with T1DM, 429 girls, mean age 12.14 ±4.0 years was retrospectively retrieved 
from medical records. Patients with T1DM and CD were selected and a detailed analysis of CD prevalence and its clinical characteristic 
at the time of CD diagnosis was performed. The data were compared with the previous data from our center published a decade ago. 
Results: CD was suspected in 85/880 patients (9.65%) on the base of results of serological tests, but finally CD was diagnosed in 
73/880 patients with T1DM (8.3%), in 53/429 girls (12.3%) and in 20/451 boys (4.4%). Most patients (71%) had CD diagnosed after 
T1DM onset. The majority of CD patients (72%) was asymptomatic. The CD diagnosis was not associated with inappropriate metabolic 
control of diabetes. The onset age of diabetes in children with CD was significantly lower than in those without CD (5.8 ±3.6 years vs. 
7.56 ±4.0 years, p = 0.04). The prevalence of CD is significantly higher than a decade ago in our center (8.3% vs. 5.7%, p = 0.001). 
Conclusions: In light of increasing prevalence of mainly asymptomatic CD in patients with T1DM, CD screening is necessary. How-
ever positive serological tests, which are currently used in screening, and are the first step of diagnostics, in some patients allow only 
to suspect the CD and further diagnostic steps should be performed.
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Streszczenie
Wstęp: Celiakia (celiac disease – CD) jest autoimmunizacyjną chorobą systemową, jedną z chorób najczęściej współistniejących 
z cukrzycą typu 1 (type 1 diabetes mellitus – T1DM). 
Cel pracy: Analiza częstości występowania celiakii i jej obrazu klinicznego w populacji dzieci i młodzieży z cukrzycą typu 1. 
Materiał i metody: Przeprowadzono retrospektywną analizę danych z dokumentacji medycznej 880 pacjentów z cukrzycą, 
429 dziewcząt i 451 chłopców, w wieku 12,14 ±4,0 lat. Wyodrębniono grupę pacjentów z cukrzycą i celiakią, analizując częstość 
występowania celiakii i jej obraz kliniczny przy rozpoznaniu. 
Wyniki: Celiakię zdiagnozowano u 73/880 pacjentów z T1DM (8,3%), u 53/429 dziewcząt (12,3%) i 20/451 chłopców (4,4%), chociaż 
CD była podejrzewana u 85/880 pacjentów (9,65%) na podstawie wyników badań serologicznych. U większości pacjentów CD została 
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Introduction 
Celiac disease (CD) is an immune-mediated systemic disor-
der elicited by gluten and related prolamines in genetically sus-
ceptible individuals and characterized by the presence of a vari-
able combination of gluten-dependent clinical manifestations, 
CD-specific antibodies, HLA-DQ2 or HLA-DQ8 haplotypes, and 
enteropathy [1, 2]. Typical celiac disease includes malabsorp-
tion syndrome characterized by gastrointenstinal and extraint-
estinal signs and symptoms. There are chronic or intermittent 
diarrhea, abdominal distention or cramping, flatulence, steator-
rhea, nausea or vomiting, chronic abdominal pain, constipation, 
weight loss, and abnormal liver biochemistry. Extraintestinal 
signs and symptoms include iron-deficiency anemia, chronic 
fatigue, failure to thrive, stunted or short stature, delayed puber-
ty, amenorrhea, recurrent aphtous stomatitis, dermatitis herpeti-
formis – like rash, fracture with inadequate traumas, osteopenia, 
osteoporosis. In recent years, an increasing number of cases 
with atypical symptoms have also been diagnosed at older 
ages [3, 4]. Atypical forms of CD manifest as short stature, iron 
deficiency anemia or delayed puberty without gastrointestinal 
symptoms. Screening programs in apparently healthy individu-
als have identified a category of silent and latent celiac disease, 
characterized by the absence of sufficient clinical symptoms to 
warrant clinical suspicion of CD, but with the presence of typical 
immunologic and histologic findings compatible with CD [3–5]. 
Screening programs include as well patients with symptoms 
of the disease as asymptomatic patients with increased risk of 
CD, such as concomitant T1DM, Down syndrome, autoimmune 
thyroid disease, Turner syndrome, Williams syndrome, selective 
immunoglobulin A (IgA) deficiency, autoimmune liver disease, 
and first-degree relatives with CD [1]. 
Celiac disease is an autoimmune disease, which, besides 
autoimmune thyroid disease, is one of the most frequent 
concomitant diseases occurring in type 1 diabetes mellitus 
(T1DM) [6]. Celiac disease can be missed in people with T1DM 
as certain symptoms can be attributed to the diabetes (the ten-
dency to hypoglycemia, poor appetite, low body mass and short 
stature) or it is asymptomatic, that’s why screening has been 
undertaken. The prevalence of CD in T1DM varies from 0.8% 
to 16.4% and it is significantly higher comparing to the 0.5–1% 
prevalence in general population [7–9]. T1DM and CD are au-
to-immune, inflammatory diseases for which the genetic back-
ground is very important [10]. HLA analysis indicated that the 
T1DM high-risk genotype, DQ2.5/DQ8, predisposes to T1DM 
and CD autoimmunity [6]. In addition to the overlap in HLA gene 
between T1DM and CD, it was revealed that non-HLA genes can 
overlap as well [6, 10]. There has been recently noticed increase 
of autoimmune diseases. In the years 1989–2005 the T1DM inci-
dence rate in the region of Upper Silesia (population representa-
tive of Poland) increased by over 260% [11]. In many Western 
countries the prevalence of CD shows an increasing tendency 
[12, 13], hence the attempt to reassess this phenomenon in chil-
dren with type 1 diabetes treated at our Centre. The research re-
garding the concomitance of T1DM and CD was also carried out 
a decade ago and published by Grzenda-Adamek et al. [14].
The aim of our study was to assess the prevalence and 
analyze the clinical characteristics of CD in the homogenous 
Caucasian population of children suffering from type 1 DM from 
a single pediatric center in Central Europe.
Material and methods 
There were 880 Caucasian children (451 boys and 429 girls), 
patients of our Department, with a mean age of 12.1 ±4.0, with 
type 1 diabetes mellitus (T1DM) included into the study in 2017. 
They represented 90% of all children with T1DM treated in our 
Department. Among them, patients with coexisting CD were 
selected. 
All our patients with T1DM are under screening for celiac 
disease according to the modified respective The European So-
ciety for Paediatric Gastroenterology Hepatology and Nutrition 
(ESPGHAN) guidelines with the accordance with Polish “Guide-
lines on the management of diabetic patients” [1, 15]. In 2017 
according to ESPGHAN all asymptomatic patients with higher 
risk for CD in compare to general population should have ge-
netic tests as first step of CD diagnostics. If they are HLA DQ2, 
DQ8 negative, CD could be excluded without further tests [1]. 
However most our patients with T1DM (even 97% of them from 
the data regarding pediatric population from our country) have 
HLA DQ2 and/or DQ8 positive, therefore we omit genetic tests 
in the diagnostic of CD and we start with serological tests, as 
it is recommended currently by ESPGHAN [2,  16]. At diabe-
tes onset the serum levels of total IgA and tissue transgluta-
minase 2 antibodies (anti-tTg) or anti-endomysium antibodies 
(EMA) IgA class were measured. In cases of negative results 
of these tests, the tests of anti-tTg or EMA (EMA was assessed 
mainly before 2007) were repeated every year. In patients with 
zdiagnozowana już po rozpoznaniu T1DM, u 19/73 (26%) pacjentów, CD i T1DM były rozpoznane w tym samym czasie. Większość 
pacjentów z CD (72%) przy rozpoznaniu nie miało objawów choroby. Dzieci z CD i T1DM zapadały na cukrzycę w młodszym wieku 
niż dzieci z cukrzycą bez celiakii. Wiek rozpoznania cukrzycy u dzieci z CD był niższy niż wiek rozpoznania cukrzycy u dzieci bez CD 
(5,8 ±3,6 roku vs 7,56 ±4,0 roku, p = 0,04). Częstość występowania CD towarzyszącej T1DM w populacji pediatrycznej rasy kauka-
skiej aktualnie wynosi 8,3% i jest znamiennie wyższa niż dekadę temu (dane z naszego ośrodka to 5,7%), p = 0.001. 
Wnioski: Ze względu na narastającą częstość występowania głównie bezobjawowej celiakii u pacjentów z T1DM, monitorowanie 
populacji pediatrycznej w kierunku CD, aktualnie oparte na badaniach serologicznych, jest ciągle konieczne. Jednakże pozytywny 
wynik testów serologicznych u części pacjentów musi zostać zweryfikowany dalszymi badaniami diagnostycznymi. 
Słowa kluczowe:
celiakia, dzieci i młodzież, objawy, częstość występowania, cukrzyca typu 1.
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simultaneous IgA deficiency, the IgG class antibodies were as-
sessed. In accordance with the “Guidelines on the manage-
ment of diabetic patients” [15], the screening should take place 
every one-two years for the first 10 years of the T1DM duration, 
and is discontinued if no clinical symptoms occur. 
The diagnosis of CD was based on elevated anti-tTg anti-
bodies and EMA, and in most cases on positive histopathologi-
cal changes in the duodenal mucosa. After 2012, in patients 
with clinical symptoms of CD and with the concentration of anti-
tTg antibodies higher than 10-times the upper normal limit and 
with positive EMA and genetic test, CD was diagnosed avoiding 
duodenal biopsy. Before 2012 all patients underwent duodenal 
biopsy to diagnose CD. The serum level of EMA was measured 
using indirect immunofluorescence test (Euroimmun, Ger-
many). The serum levels of tTg as well IgA class as IgG were 
measured using enzyme immunoassays with a single antigen 
– ELISA (Euroimmun, Germany). Serum level of IgA was mea-
sured using nephelometry method on a Siemens Dade-Behring 
BN II nephelometer (Siemens, Germany). For the assessment 
of changes in duodenal mucosa, gastroduodendoscopy and 
the tissue biopsy were performed. Two bioptats from bulbus 
and at least four bioptats from pars descendens were taken 
during a gluten-containing diet. In order to grade the samples 
of the mucosa, the Marsh-Oberhuber classification was used. 
Histological lesions of Marsh 2 and 3 are known to be typical for 
celiac disease and confirmed the diagnosis of CD. 
The retrospective analysis of the hospital data was per-
formed. The Approval of Ethics Committee of Jagiellonian Uni-
versity nor Informed Consent from the parents of the patients 
were not need to perform the study. The analysis concerned: 
sex, time of the diagnosis of CD with regard to onset of T1DM, 
HbA1c level at the time of the CD diagnosis, and symptoms in 
patients at the time of diagnosis such as abdominal pain and 
diarrhea, anemia, and short stature. The HbA1c levels were 
measured by a standardized IFCC method.
The obtained data were compared with the data from our 
center presented a decade ago [14]. Statistical analysis of the 
clinical data was made using Excel (Microsoft Office Professional 
Plus 2016, PL). Variables are presented as mean with sd. Differ-
ences between T1DM patients with and without coeliac disease 
and between the current data and the previous data from our 
center were determined by Student’s t test. Statistical tests were 
two-sided. A p value < 0.05 was used as statistically significant.
Results
CD was suspected in 85 of 880 patients with DM (9.6%), 
in 61 of 429 girls (14.2%) and in 23 of 451 boys (5.1%) on the 
base of serological test. In 5 (5.8%) of those patients, 3 boys 
and 2 girls, immunoglobulin A (IgA) deficiency was diagnosed 
(total IgA below 0.2 g/l), and therefore the conclusions about 
serological positivity were drawn from the results of IgG class 
CD-specific antibody tests. Finally CD was diagnosed in 73 pa-
tients (8.3%), in 53 girls (12.3%) and 20 boys (4.4%). All patients 
with CD diagnosed before 2012 underwent duodenal biopsy, 
after 2012 in two patients with CD symptoms, positive EMA and 
positive genetic tests, and the concentration of anti-tTg antibod-
ies higher than 10-times the cut-off, CD was diagnosed without 
duodenal biopsy. Among 12 (14%) of seropositive patients in 
whom finally CD was excluded, six (7%) had negative results of 
duodenal mucosa biopsy, in other six (7%) the concentration of 
anti-tTg antibodies gradually normalized without the introduction 
of a gluten-free diet and duodenal biopsy was not performed.
Most T1DM patients with CD have CD diagnosed after 
diabetes onset 52/73 (71.2%). The median time of CD the di-
agnosis after T1DM diagnosis in the total subject group was 
28.4 ±30.8 months, in girls 26.3 ±31.6 months and in boys 
32.5 ±29.2 months. In 19/73 patients with T1DM and CD (26% 
and 2.2% of all T1DM patients), CD was diagnosed at the mo-
ment of the diagnosis of T1DM, only 2 patients (2.7%) had CD 
diagnosed 22 months and 24 months before DM onset. 
The age of T1DM onset was lower in patients with concomi-
tant CD compared to patients with isolated T1DM (5.8 ±3.6 years 
vs. 7.6 ±4.0 years, p = 0.04). 
The majority of patients 53/73 (72.2%) with CD presented 
without any typical signs and symptoms of CD. In 8/73 (11%) of 
patients short stature was the only presentation of CD, in further 
8/73 (11%) abdominal pain, in 3/73 (4.1%) anemia, and in 3/73 
(4.1%) diarrhea suggested CD. 
The mean HbA1c level at the time of CD diagnosis was not 
significantly different between patients with DM and CD and 
patients with DM without CD as well when CD was diagnosed 
simultaneously with DM (11.7 ±2.4% vs. 11.4 ±3.2%), as when 
CD was diagnosed later then T1DM (7.2 ±1.2% vs. 7.1 ±1.5%).
A decade ago the prevalence of CD in our patients with 
T1DM was assessed as 5.7%. In our previous study, published 
in 2007, 459 patients with DM (214 girls, mean age 13.7 years) 
were screened for EMA, which were positive in 38 of them. 
Out of the 8 patients initially positive, the EMA of 7 later be-
come negative. In 26 patients finally CD was diagnosed on the 
base of the positive result of duodenal biopsy. No differences 
in HbA1c levels, insulin requirement and frequency of severe 
hypoglycemia, and moreover height-SDS and BMI-SDS, were 
found between children with diabetes with and without CD. As 
currently, patients with T1DM and CD had an earlier onset of di-
abetes in compared to those without CD (6.5 vs. 8.6 years) [14].
The prevalence of CD among patients with T1DM currently is 
significantly higher than decade ago (8.3% vs. 5.7%, p = 0.001).
Discussion
Regarding the newest data, the global prevalence of CD 
based on serologic test results is 1.4% and based on biopsy 
results is 0.7% [8]. On the base of our assessment the preva-
lence of CD is much frequent in young patients with T1DM than 
in general population. Our study showed concomitance of CD 
and T1DM at the level of 9.3% based on serologic test results 
and 8.3% confirmed on biopsy results. Data from other studies 
reported the different prevalence of CD in patients with T1DM 
from 0.8% to 16.4% around the world [7]. The nest data report 
that CD was present in 2652 subjects (4.5%), with different prev-
alence among regions: from 1.9% in Asia/Middle East to 6.9% 
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in Australia/New Zealand [17]. The greatest rates of comorbidity 
are reported in Algeria, India and Saudi Arabia [18]. It could 
be related with the highest ratio of per capita wheat consump-
tion in these regions, as well as with high occurrence of genetic 
predisposition (proper genes’ polymorphisms) [6]. Differences 
in prevalence of CD among counties could be also explained 
by different environment factors, for example exposition to vi-
ruses. The increased risk conferred by the interaction between 
enteroviruses and higher gluten intake indicate a cumulative ef-
fect of these factors in the development of CDA in genetically 
increased patients [19]. However according to the newest ESP-
GHAN 2020 recommendations genetic testing is not necessary 
to make diagnosis of CD, the previous 2012 guidelines recom-
mended HLA DQ2/DQ8 typing as the screening test in asymp-
tomatic patients with high risk of CD development (e.g.T1DM) 
[1, 2]. All our patients were diagnosed when the previous criteria 
were in force. In the case of negative HLADQ2/8, CD could be 
excluded. However the latest data indicate that genotyping HLA 
DQ2/DQ8 as a negative screening has limited use in assessing 
the risk of CD at the diabetes onset and does not allow to verify 
the diagnosis of CD in doubtful situations [20]. When genetic 
tests were unavailable, anti-tTg and total IgA level were used as 
the initial screening tests. Currently, according new 2020 ESP-
GHAN guidelines, anti tTg and total IgA is recognized to be the 
initial screening test in asymptomatic population with high risk 
of CD development (e.g. T1DM) [2, 15]. Our study confirmed 
that 72% of patients with T1DM were asymptomatic, and a sub-
stantial amount of CD cases are diagnosed after the diagnosis 
of T1DM (74%), therefore the screening of CD using antibody 
measurement, remains an invaluable device in the process of 
diagnosis of CD among T1DM patients. Before 2020, there were 
some discrepancies in literature concerning HLA DQ2/DQ8 typ-
ing as the screening test for CD among asymptomatic patients 
with risk factors of CD development. Although recommenda-
tions of the ESPHGAN presented in 2012 advised genetic tests, 
some authors showed that HLA DQ2/DQ8 typing as a screening 
test in T1DM is neither distinctive nor cost-effective, because the 
test is positive up to 86%, 92% or even 97.6% (our country) pa-
tients with T1DM [16, 23, 24]. In our Department we had similar 
observations of small clinical usefulness of genetic tests of hap-
lotypes, therefore the measurement of anti-tTg and next EMA 
levels was assumed as a relatively cheap and efficient screen-
ing tool for diagnosis of CD among asymptomatic patients with 
T1DM. This choice was moreover based on numerous scientific 
studies that have confirmed the high sensitivity and specificity 
of both types of antibodies for CD diagnosis, which for EMA IgA 
are estimated to be 95% and 99%, respectively [25], and for 
anti-tTg IgA 96.4% and 97.7%, respectively [2]. 
Our study showed higher occurrence of CD among girls 
with T1DM than among boys (13.9% and 4.9% respectively). 
It is in an agreement to the latest data reported by Taczanow-
ska et al., but seems to be incoherent with data presented by 
Kylökäs et al. [17, 26]. Kylokas et al. analyzed 984 women and 
374 men with CD, and regardless of this disproportion, they 
revealed higher prevalence of DM1 among men with celiac 
disease compared with corresponding women (respectively: 
8% vs. 1.8%) [26]. It could be due to the fact that T1DM oc-
curs more frequently among men than women. The underlying 
cause of the discrepancy of our study and Kylokas et al. may lie 
in the different methodology. In our study, we took into consid-
eration the whole group of our patients with T1DM with an ap-
proximately equal distribution of men and women with T1DM, 
and the comorbidity was found to be higher among women, 
because CD more likely occurs among women in general pop-
ulation. In contrast Kylokas et al. analyzed the occurrence of 
T1DM in the group of patients with CD [26].
Our data showed similar mean HbA1c levels in patients with 
CD in comparison to patients with T1DM without CD as well 
as when CD was diagnosed at the moment of T1DM onset or 
when CD was confirmed after T1DM occurrence (respectively: 
11.7% vs 11.4% and 7.2% vs 7.1%). In our study we did not 
analyzed if the introduction of GFD influenced the HbA1c level. 
This issue is still disputable, because metabolic consequenc-
es of CD in children with T1DM differ around the world  [17]. 
Some studies show the lack of effect of GFD on the results of 
metabolic control, but only the increase of insulin requirement 
[27–30]. Co-existence of T1DM and active CD predisposes to 
frequent episodes of hypoglycemia. Hypoglycemic episodes 
activate well-known counter regulatory mechanisms (activa-
tion of adrenergic system, cortisol, growth hormone produc-
tion) leading respectively to hyperglycemic episodes [31, 32]. 
However it is known that these mechanisms are weaker in 
patients with T1DM, due to several factors including early loss 
of the plasma glucagon responses to hypoglycemia, blunted 
epinephrine responses during sleep, impaired glucose counter 
regulation resulting from recurrent episodes of mild hypoglyce-
mia especially during the night, progressive loss of the modu-
lating effects of residual endogenous insulin secretion [33, 34]. 
We observe that T1DM patients rescuing from hypoglycemia 
very often take too much carbohydrates, and therefore present 
with hyperglycemia after hypoglycemia episodes. A potential 
non-strict following GFD could be also the reason of the lack of 
differences in the level of HbA1c between patients with T1DM 
and CD, and those without CD. 
The mutual influence of these two autoimmune disorders 
is marked also in the earlier age of onset of T1DM among pa-
tients with two autoimmune disorders than when only T1DM 
is diagnosed [13], which was also confirmed in our study 
(5.8 ±3.6 years vs. 7.6 ±4.0 years). It can be associated with an 
acceleration of the autoimmune process of T1DM by activation 
of immunological system in active CD. It has been suggested 
that the exposure to gluten in genetically predisposed individuals 
may be a possible trigger of type 1 diabetes and other autoim-
mune diseases [35, 36]. Some authors proved the presence of 
organ specific antibodies (e.g. antithyroid) in patients with con-
firmed CD and lack of detectable antibodies after elimination of 
gluten in the diet [37–39]. It suggests, despite other autoimmune 
disorders not being gluten-dependent, GFD can also prevent 
patients with confirmed CD from developing other autoimmu-
nological disorders. Our data indicate that 26% of patients with 
T1DM have CD diagnosed at the time of DM onset, in similar 
Italian study from 2002 60% of CD cases were already present 
Celiac disease and type 1 diabetes mellitus
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at diabetes onset [35]. The majority of our patients (71%) was 
diagnosed after DM onset, mean 28.4 ±30.8 months later. The 
other studies confirmed increasing prevalence of CD during sub-
sequent years of patients observation [40, 41]. What is worth un-
derlining, comparing our current results with the results from our 
center published in 2007, an increasing prevalence of comorbid-
ities of T1DM and CD is noted (respectively 8.3% vs. 5.7%) [10]. 
It could be related to raising occurrence each of CD and T1DM in 
the population [9, 10, 42–45]. Because the pool of genes did not 
change in this homogenous population during several years of 
observation, our results allow to confirm a potential influence of 
environmental factors involved in development of both diseases. 
At the time of CD diagnosis most of our patients were asymp-
tomatic in their presentation, and no signs of overt malnutrition 
had been documented. Perhaps they did not develop the com-
plete spectrum of symptoms of this disease thanks to the annual 
screening program. Therefore our study emphasizes the impor-
tance of screening for celiac diseases in this group of patients. In 
accordance with new ESPGHAN Guidelines for Diagnosing CD 
2020, we do recommend measurement of anti-tTg and EMA lev-
els as screening tool for CD diagnosis in asymptomatic patients 
with T1DM. However we should remember that 14% of patients 
who are seropositive regarding anti-tTg and EMA could do not 
be in fact diagnosed as CD, because they have negative results 
of duodenal mucosa biopsy. These patients should be still ob-
served and screened. Disadvantage of our study is that not all 
our patients with T1DM were included into the study. However 
90% of them in our opinion is a representative group. Moreover 
we did not evaluate the results of the introduced GFD on clinical 
outcome of diabetes mellitus, what could be very interesting.
Conclusions
The prevalence of CD in the homogenous Caucasian popu-
lation of Central Europe is 8.3%. The occurrence of CD is sig-
nificantly higher in girls (13.9%) than boys (4.9%) with T1DM. 
An increasing rate of comorbidities of T1DM and CD has been 
noted in our population during the period of last 10 years (re-
spectively 8.3% vs. 5.7%). The majority of patients with T1DM 
presented with asymptomatic CD (72%). In most patients CD 
was diagnosed after T1DM onset (71%). The CD diagnosis was 
not associated with inappropriate metabolic control of DM, but 
is was associated significantly with the younger age of the T1DM 
onset. Our data confirms the importance of the use of screen-
ing tests CD in children and adolescents with T1DM, however 
positive serological tests, which are the first step of screening, in 
some patients allow only suspect the CD and further diagnostic 
steps should be performed. 
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